As with verteporfin, many other compounds, such as CA3 and CPD3.1 [128–130], are also gradually identified to be able to interfere with YAP/TAZ-TEAD-mediated activity, thereby inhibiting tumour cell growth. Here, YAP1 is linked to neoplasm.